Reducing Risks Involving Technology ControlBy Miriam Bello | Mon, 05/18/2020 - 14:08
Q: What makes Escala Biomédica the perfect ally for companies seeking advice on technology management and medical infrastructure?
A: We have had more than 100 successful consultancy projects. In some of these, we have helped to reduce 20 percent of the cost for medical equipment with our technology management solutions.
The company has over 30 years of experience in medical technology, focusing on helping doctors to provide better treatment to their patients. In our last project, for example, we studied the client’s system and we proposed technological solutions to strengthen and expand its reach. We analyzed the risks involved in the acquisition, the installation and the actual use of that new technology.
Q: What risks do clients face when implementing new technologies and how does Escala Biomédica minimize these?
A: The risk is always related to the patient, so we are looking to reduce risks involving technology control. There is a techno-vigilance standard that monitors the reactions provoked by medical devices, which we use to ensure patient safety. Our expertise is exactly in identifying risks so clients can have some control over them.
One of the most common risks we have identified is infection control, which is not commonly thought to be related to infrastructure. However, having the right facility entrances, for example, can prevent the spreading of viruses and eventually make the place less vulnerable to infections. Our clients need to be fully aware of the state of their infrastructure, the information they are going to handle and have access to and how they are going to operate their medical devices. Furthermore, they have to make sure their staff has the proper training to use the equipment correctly.
Q: What are the predominant technologies in which hospitals tend to invest and how could this change in the future?
A: This would depend on what patients require and on the needs that the current technologies address. The market right now is focused on oncology; new chemotherapy clinics are opening, as well as companies focused on medicine and equipment to treat cancer. The public and private sectors know this is a priority for Mexico and they have given it the attention it requires. Diabetes is also one of the top priorities for the sector. This epidemic pushed Mexico to strengthen its focus on this problem and has also set a direction for the market.
Q: How do you think technology will change patient care?
A: Noninvasive methods have improved care, as well as rehabilitation and recovery processes. All new changes push the healthcare system to evolve and to give better treatment to patients. In some cases, technology also speeds up treatment, which means fewer costs for the hospital and a faster ROI on their investment. It is important to find a balance, however. Technology is not cheap and sometimes it can become a financial burden or fail to deliver what was promised. That is why Escala Biomédica takes its precautions with recently launched technologies.
Q: Who are Escala Biomédica’s main clients and what new players are you planning to approach?
A: Public hospitals have been our main clients and we want to keep helping them and their medical staff with their decision-making. We also want to guide companies that sell medical equipment toward hospitals and clinics that can take advantage of their solutions. Working with private hospitals is an important goal, as well. We see a great deal of potential in contributing to their biomedical engineering, technology evaluation and safety management departments.
Q: What are Escala Biomédica’s main goals for 2020-2021?
A: Repositioning Escala Biomedica is one of our priorities. Mexico faced a consulting crisis that affected the company but this pushed us to grow and to amplify our coverage. We want to work with new clients on specific problems that Escala Biomédica can potentially solve.
Escala Biomédica is a multidisciplinary team of consultants. Its practice focuses on innovation and professional training of consultants, as well as experience and documentation of best clinical practices.